Article
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Oct 2011
Nakamura Tomomi, Sueoka-Aragane Naoko, Iwanaga Kentaro, Sato Akemi, Komiya Kazutoshi, Abe Tomonori, Ureshino Norio, Hayashi Shinichiro, Hosomi Toshiya, Hirai Mitsuharu, Sueoka Eisaburo, Kimura Shinya
Abstract excerpt
INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors are widely used to treat lung adenocarcinomas with EGFR-activating mutations. However, half of the patients acquire resistance because of the gatekeeper T790M mutation. Noninvasive mutation detection system is desired considering the difficulty in obtaining tissue specimens during disease progression. METHODS: Sixty-seven plasma DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.